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Hepatocyte nuclear factor-4{alpha} and bile acids regulate
human concentrative nucleoside transporter-1 gene expression
Abstract
The concentrative nucleoside transporter-1 (CNT1) is a member of the solute carrier 28 (SLC28) gene
family, and is expressed in the liver, intestine, and kidneys. CNT1 mediates the uptake of naturally
occurring pyrimidine nucleosides, but also nucleoside analogues used in anticancer and antiviral
therapy. Thus, expression levels of CNT1 may affect the pharmacokinetics of these drugs and the
outcome of drug therapy. Because little is known about the transcriptional regulation of human CNT1
gene expression, we have characterized the CNT1 promoter with respect to DNA response elements and
their binding factors. The transcriptional start site of the CNT1 gene was determined by 5'-RACE. In
silico analysis revealed the existence of three putative binding sites for the nuclear receptor hepatocyte
nuclear factor-4alpha (HNF-4alpha) within the CNT1 promoter. A luciferase reporter gene construct
containing the CNT1 promoter region was transactivated by HNF-4alpha in human cell lines derived
from the liver, intestine, and kidneys. Consistent with this, we showed in electromobility shift assays
that HNF-4alpha specifically binds to two conserved direct repeat-1 (DR-1) motifs within the proximal
CNT1 promoter. In cotransfection experiments, the transcriptional coactivator peroxisome
proliferator-activated receptor-gamma coactivator-1alpha (PGC-1alpha) further increased, whereas the
bile acid-inducible corepressor small heterodimer partner (SHP) reduced, HNF-4alpha-dependent CNT1
promoter activity. Consistent with the latter phenomenon, CNT1 mRNA expression levels were
suppressed in primary human hepatocytes upon bile acid treatment. Supporting the physiological
relevance and species-conservation of this effect, ileal Cnt1 mRNA expression was decreased upon bile
acid feeding and increased upon bile duct ligation in mice. Key words: nucleoside transport, bile acids,
transcriptional regulation, nuclear receptors.
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ABSTRACT 
 
 The concentrative nucleoside transporter-1 (CNT1) is a member of the solute carrier 28 
(SLC28) gene family, and is expressed in the liver, intestine, and kidneys. CNT1 mediates the 
uptake of naturally occurring pyrimidine nucleosides, but also nucleoside analogues used in 
anticancer and antiviral therapy. Thus, expression levels of CNT1 may affect the 
pharmacokinetics of these drugs and the outcome of drug therapy. Because little is known 
about the transcriptional regulation of human CNT1 gene expression, we have characterized the 
CNT1 promoter with respect to DNA response elements and their binding factors. The 
transcriptional start site of the CNT1 gene was determined by 5`-RACE. In silico analysis 
revealed the existence of three putative binding sites for the nuclear receptor hepatocyte 
nuclear factor-4α (HNF-4α) within the CNT1 promoter. A luciferase reporter gene construct 
containing the CNT1 promoter region was transactivated by HNF-4α in human cell lines 
derived from the liver, intestine, and kidneys. Consistent with this, we showed in 
electromobility shift assays that HNF-4α specifically binds to two conserved direct repeat-1 
(DR-1) motifs within the proximal CNT1 promoter. In cotransfection experiments, the 
transcriptional coactivator peroxisome proliferator-activated receptor-γ coactivator-1α (PGC-
1α) further increased, whereas the bile acid-inducible corepressor small heterodimer partner 
(SHP) reduced, HNF-4α -dependent CNT1 promoter activity. Consistent with the latter 
phenomenon, CNT1 mRNA expression levels were suppressed in primary human hepatocytes 
upon bile acid treatment. Supporting the physiological relevance and species-conservation of 
this effect, ileal Cnt1 mRNA expression was decreased upon bile acid feeding and increased 
upon bile duct ligation in mice.  
Keywords: nucleoside transport, bile acids, transcriptional regulation, nuclear receptors
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INTRODUCTION 
 
The uptake of naturally occurring nucleosides as well as nucleoside analogue drugs into cells 
relies on equilibrative and concentrative plasma membrane nucleoside transporters, which are 
encoded by members of two distinct gene families, the solute carrier families SLC28 and 
SLC29. CNT1 (SLC28A1) is one of the three members of the solute carrier gene family 
SLC28 of active, concentrative, and Na+-dependent nucleoside transporters (21). While the 
main physiological function of nucleoside transporters is to salvage nucleosides from blood, 
there is growing evidence that they are also involved in regulatory processes by modulating 
extracellular adenosine concentrations (27). CNT1 transports naturally occurring pyrimidine 
nucleosides (50). In addition, the transport substrates for CNT1 include several nucleoside 
analogue drugs used in antiviral and anticancer therapy, such as zidovudine, cytarabine, and 
gemcitabine (21). Detailed knowledge of the regulation of CNT1 gene expression may help us 
to understand the mechanisms that influence the pharmacokinetics of drugs transported by 
CNT1, and potentially enable us to modulate CNT1-mediated drug transport in a defined 
manner. 
 The CNT1 mRNA is most abundantly expressed in human liver and kidneys (45), and 
is also present in duodenum and ileum (37). The CNT1 protein is localized at the apical 
membranes of enterocytes and proximal tubules of the kidney (18). In human hepatocytes, 
CNT1 has been shown to be localized at both the basolateral and canalicular membranes (19). 
Whereas the transport characteristics of CNT1 have been studied extensively (43), little is 
known about the regulation of CNT1 expression levels, and no promoter analyses have been 
published to date. CNT1 expression has been shown to be altered in tumours of various tissue 
origin in comparison with normal tissue (45) and the loss of CNT1 protein expression has been 
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correlated with histological subtypes of gynaecological tumours characterized by poor 
prognosis (11). Furthermore, CNT1 expression is upregulated in adipose tissue of HIV-infected 
patients (22). The human CNT1 gene exhibits a high degree of genetic and functional variation. 
Many single nucleotide polymorphisms in the coding region appear to be tolerated, although 
genetic variants that alter gemcitabine transport kinetics have been described (20, 29). Cnt1 
expression is higher in differentiated than undifferentiated rodent hepatocytes (6) and is 
increased after partial hepatectomy in rats (12). Further evidence that CNT1 expression is 
associated with cell maturation comes from immunohistochemistry of human duodenal 
biopsies that showed almost absent CNT1-specific staining of crypt cells, but readily detectable 
expression in mature enterocytes (18). Cnt1 expression levels are increased in jejunum of 
starved rats or rats fed a nucleotide-deficient diet, which indicates that substrate availability 
may modulate its expression (55). Moreover, Cnt1 mRNA expression is increased in hearts of 
streptozotocin-induced diabetic rats (44) and decreased upon insulin treatment in cultured 
cardiac fibroblast (46). Furthermore, hepatic CNT1/Cnt1 protein expression is increased by the 
cytokines TNF-α and IL-6 in cultured cells and in vivo in rats (14).  
 Our aim was to characterize the mechanisms by which the expression levels of the 
CNT1 gene are regulated in human cell lines derived from liver, intestine, and kidneys, as well 
as in primary human hepatocytes. We show that the promoter region of the CNT1 gene is 
regulated by the nuclear receptor HNF-4α, the transcriptional coactivator PGC-1α, and bile 
acids, and have identified the CNT1 promoter elements that mediate these regulatory events. 
Given the high conservation of these promoter elements between humans and rodents, we 
further studied, whether murine Cnt1 gene expression is regulated by bile acids in two different 
cholestatic mouse models. 
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MATERIALS AND METHODS  
 
 Chemicals. Deoxyadenosine 5’-[α-32P]-triphosphate (6000 Ci/mmol) was purchased 
from Perkin Elmer (Schwerzenbach, Switzerland). Restriction enzymes were from Roche 
Diagnostics (Rotkreuz, Switzerland),  PuRe Taq Ready-To-Go PCR beads from GE Healthcare 
(Glattbrugg, Switzerland) and T4 DNA Ligase from Promega (Dübendorf, Switzerland). The 
oligonucleotides were synthesized by Microsynth (Balgach, Switzerland). Other chemicals 
were purchased from Sigma-Aldrich (Buchs, Switzerland), unless stated otherwise. 
 Cell culture. The human hepatoma cell line Huh7 (JCRB Cell Bank, Japan) was 
cultured in RPMI-1640 medium (Sigma-Aldrich) supplemented with 10% fetal bovine serum 
(Sigma-Aldrich), 100 U/ml penicillin and 100 µg/ml streptomycin (Invitrogen, Basel, 
Switzerland).  The human renal adenocarcinoma cell line ACHN (LGC Promochem, Wesel, 
Germany) was maintained in Eagle`s minimum essential medium (Sigma-Aldrich) 
supplemented with 10% fetal bovine serum, 100 U/ml penicillin (Invitrogen) and 100 µg/ml 
streptomycin (Invitrogen). The human colon carcinoma cell line Caco2 (LGC Promochem) 
was grown in Dulbecco`s modified Eagle`s medium (Sigma-Aldrich) supplemented with 10% 
fetal bovine serum, 100 U/ml penicillin and 100 µg/ml streptomycin. Fresh primary human 
hepatocytes were purchased from Lonza (Verviers, Belgium). Upon arrival the cells were 
transferred into Hepatocyte Maintenance Medium (HMM) supplemented with HMM Single 
Quots (Lonza), 100 U/ml penicillin and 100 µg/ml streptomycin. Cells were cultured at 
+37°C in a humidified atmosphere containing 5% CO2.  
 5`-Rapid amplification of cDNA ends (5'-RACE). We carried out 5`-RACE using the 
SMART RACE cDNA Amplification Kit (Clontech, Saint-Germain-en-Laye, France) with 
one µg of total liver RNA (Clontech) as a template. The oligonucleotide primer used for 
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amplification of the cDNA is listed in Table 1. The PCR product was cloned into pGEM-T 
vector (Promega) and sequenced (Microsynth). 
 RNA isolation, reverse transcription, and real-time PCR. Fresh primary human 
hepatocytes were treated with 50 μM chenodeoxycholic acid (CDCA) or the vehicle DMSO 
for 16 hours. Total RNA was isolated using the TRIzol reagent (Invitrogen) and RNA was 
quantified spectrophotometrically at 260 nm (NanoDrop ND-1000, Witec AG, Littau, 
Switzerland). One μg of each RNA from primary human hepatocytes was reverse transcribed 
by random priming (Reverse Transcription System, Promega). Five μl of each cDNA, from 
final reaction volumes of 100 μl, were used for real-time PCR, which was performed on an 
7900HT Fast Real-Time PCR System (Applied Biosystems, Rotkreuz, Switzerland) using the 
TaqMan Gene Expression Assays Hs00188418_m1, Hs00222677_m1, Hs00230853_m1, 
Hs00161820_m1, and Hs00251986_m1 for human CNT1, SHP, HNF-4α, NTCP, and 
OATP1B3 (Applied Biosystems), respectively. Constitutively expressed human β-actin was 
measured as an internal standard for sample normalization (#4310881E, Applied Biosystems). 
Mouse RNA was isolated as described (65). Three µg of RNAs derived from mouse ileum and 
kidneys were reverse transcribed as described above. Two μl of each cDNA, from final 
reaction volumes of 80 μl, were used for real-time PCR using the TaqMan Gene Expression 
Assays Mm01315366_g1, Mm00442278_m1, Mm00433964_m1, Mm00521531_m1, 
Mm00619242_m1, and Mm00488258_m1 for mouse Cnt1, Shp, Hnf-4α, Ostα, Ostβ, and Asbt 
(Applied Biosystems), respectively. Constitutively expressed mouse hypoxanthine guanine 
phosphoribosyl transferase 1 (Hprt1; Mm01318743_m1) in kidneys and mouse villin 
(Mm00494156_m1) in ileum were measured as internal standards for sample normalization 
(Applied Biosystems). The relative mRNA levels were calculated using the ΔΔCT (comparative 
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threshold cycle) method. Each PCR was performed in triplicate. Mean treshold cycle (Ct) 
values for control samples  are shown in Supplemental Table 1. 
 Electrophoretic mobility shift assays (EMSAs). Oligonucleotides used in EMSAs were 
designed to have a 5’-AGCT overhang in the top strand and 5'-GATC overhang in the bottom 
strand when annealed, allowing radioactive labelling by fill-in reactions. 50 ng of annealed 
oligonucleotides were labelled in 20 μl reactions containing 200 U Superscript II RNase H 
Reverse Transcriptase (Invitrogen), 1x First-Strand Buffer (Invitrogen), 10 mM DTT, 250 nM 
dGTP/dCTP/dTTP, and 20 μCi [α-32P]-dATP. Unincorporated nucleotides were removed 
using Microspin G-25 columns (GE Healthcare, Otelfingen, Switzerland). 10 μg of Huh7 
nuclear extracts prepared using the NE-PER extraction kit (Pierce, Lausanne, Switzerland) 
were used for DNA-binding reactions. Protein-DNA complexes were formed in binding buffer 
(20 mM Tris-HCl, pH 8.0; 60 mM KCl; 2 mM MgCl2 12% (v/v) glycerol; 0.3 mM DTT; 87.5 
ng/μl poly(dI-dC)-poly(dI-dC)) in a total volume of 20 μl for 10 minutes at +30oC. After this, 
approximately 50000 cpm (0.5-1.5 ng) of the radioactive probes were added to reactions. In 
supershift experiments, 1 μg of HNF-4α antibody (H-171x, Santa Cruz Biotechnology Inc., 
Heidelberg, Germany) was added to the extracts 1 hour prior to the probe, and incubated at 
+4oC. In competition experiments, a 50-fold, 100-fold, or 200-fold molar excess of the 
competing probes was added simultaneously with the radioactive probe. Immediately after the 
binding reactions, the samples were loaded onto pre-electrophoresed 5% (acrylamide/bis 30:1) 
native acrylamide gels and run at 200 V in 0.5xTBE for 1.5 hours. The gels were fixed in 10% 
(v/v) acetic acid for 10 minutes, dried onto Whatman DE81 paper under vacuum, and exposed 
to Kodak BioMax MR-1 films (Sigma-Aldrich) at -80oC. 
 Reporter gene constructs and expression vectors. Based on the sequence (NC_000015) 
available in the NCBI database and the 5`-RACE result reported here, fragments corresponding 
                                                                                                                                                               
 
8
to the putative promoter region of the human CNT1 gene were PCR-amplified using the 
oligonucleotide primers shown in Table 1. PCR products were cloned into the pGEM-T vector 
and subcloned into the luciferase vector pGL3basic (Promega) to generate the CNT1 reporter 
constructs. The CNT1(-653/+110) reporter construct was obtained by digesting the CNT1(-
2450/+110) construct with the restriction enzymes SacI and XhoI and subcloning the fragment 
into pGL3basic.  Point mutations were introduced into the CNT1(-99/+110) construct using the 
QuikChange site-directed mutagenesis kit (Stratagene, Basel, Switzerland) and 
oligonucleotides listed in Table 1. The coding region of the human SHP and the human HNF-
4α genes were obtained through PCR amplification using oligonucleotide primers listed in 
Table 1 and human universal cDNA (Clontech) as a template. PCR products were cloned into 
the pGEM-T vector and subcloned into the pcDNA3.1(+) (SHP) or pcDNA3.1(-) (HNF-4α) 
vectors (Invitrogen). The sequences of all constructs were verified by DNA sequencing 
(Microsynth). The mammalian expression plasmid pcDNA3.1-HA-PGC-1α was provided by 
Dr. A. Kralli (La Jolla, CA).  
 Transient transfections and reporter assays. HepG2, Caco2, and ACHN cells were 
seeded on 48-well plates at a density of 7x105 cells/well, and cotransfected with 400 ng of the 
luciferase reporter constructs and 200 ng of the expression plasmids, using FuGENE HD 
reagent (Roche Diagnostics), at a ratio of 3 μl FuGENE HD per 1 μg DNA. To normalize the 
amount of DNA transfected, the pcDNA3.1(-) vector was added where appropriate. To control 
for transfection efficiency, 100 ng of the renilla luciferase (phRG-TK) reporter plasmid 
(Promega) were cotransfected. Cells were harvested 36 hours after transfection, and luciferase 
activities determined using the Dual Luciferase assay system (Promega) in a Luminoskan 
Ascent microplate luminometer (Thermo Fisher Scientific, Wohlen, Switzerland). Reporter 
activities obtained for the empty pGL3basic corresponding to each test condition, as well as for 
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the test construct containing the test promoter in the control conditions, were set to one and 
fold activities shown relative to this. Transfection experiments were performed at least three 
times and results are shown as mean values ± standard deviations.  
Animals. Male C57/BL6 mice were housed in a 12:12-hour light/dark cycle and 
permitted ad libitum consumption of water and a standard mouse diet. The experimental 
protocols were approved by the local Animal Care and Use Committee according to criteria 
outlined by the National Institute of Health (39). 
 Bile acid feeding. Mice were fed a diet supplemented with 0.5% or 1% (wt/wt) cholic 
acid (CA) for seven days. Control mice were fed a standard mouse diet for seven days. 
Kidneys and intestine were excised and processed as described (64). In each group three to 
five animals were studied. 
 Common bile duct ligation (CBDL). CBDL was performed as described (65). Kidneys 
and intestine were excised seven days after CBDL under general anesthesia with 10 mg 
intraperitoneal tribromomethanol (Avertin; Sigma-Aldrich) and immediately snap frozen and 
stored in liquid nitrogen until RNA extraction. In each group three to five animals were 
studied. 
 Statistical analysis. Data are reported as means ± standard deviations. Differences 
between experimental groups were analyzed by one-way ANOVA with Tukey`s post hoc test, 
using the GraphPad Prism (GraphPad Software, San Diego, CA) program. P values < 0.05 
were considered significant.  
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RESULTS 
 
Determination of the transcriptional start site of the human CNT1 gene by 5`-RACE. To 
study the function of the human CNT1 promoter in vitro, we first determined the transcriptional 
start site of the CNT1 gene by 5`-RACE using liver RNA as a template (Fig. 1A). The reverse 
primer used in the PCR was located in exon 3 (Fig. 1B). The obtained PCR product was cloned 
into the pGEM-T vector and sequenced. The transcriptional start site of CNT1 gene was 
identified 27 bp upstream of the predicted start of exon 1 according to the GenBank submission 
NM_004213 (Fig. 1C). As the ATG start codon of the CNT1 gene is located within the exon 2, 
the entire exon 1 and the first part of the exon 2 serve as a 5'-untranslated region.  
Identification of putative HNF-4α response elements in the CNT1 promoter. In an 
attempt to identify putative regulatory regions within the human CNT1 promoter region, we 
performed in silico analyses using the NUBIScan algorithm (47) and the MatInspector 
software (3). Two proximal and one distal DR-1 elements located at positions between 
nucleotides -55/-43, -71/-59, and -1857/-1845 were identified (Fig. 2A). HNF-4α has been 
previously shown to preferentially bind to DR-1 and DR-2 motifs (16). The two proximal 
CNT1 DR-1 elements differ from the consensus DR-1 element by two nucleotides and the 
more distal DR-1 element by one nucleotide. The two proximal DR-1 motifs are located in an 
evolutionary conserved region identified by using the rVISTA 2.0 tool (33). The corresponding 
rodent DR-1 elements differ from the human sequence by one nucleotide each (Fig. 2B).  
HNF-4α transactivates the human CNT1 promoter. To test whether HNF-4α is capable 
of activating human CNT1 gene expression we cloned a region of the CNT1 promoter between 
the nucleotides -2450 and +110. Huh7, Caco2, and ACHN cells were cotransfected with the 
reporter-linked CNT1 (-2450/+110) promoter, either with or without expression plasmid for 
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HNF-4α. Overexpression of HNF-4α significantly increased CNT1 promoter activity in all cell 
lines studied (Fig. 3A, 3B, 3C). To determine the region of the CNT1 promoter accountable for 
the HNF-4α-mediated effect, we created 5` deletions of the -2450/+110 fragment. Basal 
promoter activities of the CNT1 promoter deletion constructs in Huh7, Caco2, and ACHN cells 
are shown in Supplemental Figure 1. Deletion of the genomic region upstream of -341 bp did 
not significantly affect HNF-4α-mediated transactivation of the CNT1 promoter. A deletion to 
the nucleotide position of -99 slightly decreased HNF-4α-mediated upregulation of CNT1 
promoter activity. However, we could not identify any HNF-4α binding sites in the promoter 
region between nucleotides -341 and -99, and we speculate that this decrease might be due to 
an indirect effect by HNF-4α on CNT1 promoter activity. A further deletion of the CNT1 
promoter to the nucleotide position of -29 completely abolished the activation, whereas a 
promoter fragment containing nucleotides -99/+3 was still activated by HNF-4α. Thus, the 
HNF-4α-responsive region is located between the nucleotides -99 and -29 upstream of the 
CNT1 transcription start site, containing the two conserved proximal predicted HNF-4α-
binding motifs. Next, we mutated (Fig. 2A) the proximal DR-1 elements in the CNT1(-
99/+110) promoter construct, either together or separately, to test their functionality. 
Disruption of either DR-1 site alone was not sufficient to abolish HNF-4α-mediated increase in 
CNT1 promoter activity (Fig. 4). Only mutagenesis of both DR-1 elements together disrupted 
HNF-4α-mediated transactivation of the CNT1 promoter. These data demonstrate that both the 
-71/-59 and the -55/-43 DR-1 elements of the CNT1 promoter are functional mediators of the 
HNF-4α effect. 
 HNF-4α binds to the two DR-1 elements within the proximal CNT1 promoter. To verify 
whether HNF-4α can directly interact with the identified HNF-4α response elements in the 
CNT1 promoter, we performed electromobility shift assays using nuclear extracts from Huh7 
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cells and the CNT1 sequence containing the wild-type or mutated DR-1 elements as 
radiolabelled probes (Fig. 5A). Probes contained each of the two DR-1 elements separately or 
together. Nuclear proteins strongly bound to the double-stranded oligonucleotides spanning the 
CNT1 promoter region from -76 to -54 and -60 to -38, containing either DR-1 site separately, 
and from -76 to -38, containing both DR-1 sites together. The protein-DNA complexes were 
supershifted after addition of an HNF-4α antibody (Fig. 5A), whereas antibodies against other 
nuclear receptors  (RXRα, PPARα, PPARβ, PPARγ, RAR) had no effect (data not shown). 
Mutagenesis of either one DR-1 motif, or both of the DR-1 elements simultaneously disrupted 
the HNF-4α binding.  
To further confirm the specificity of HNF-4α-binding to the DR-1 elements we 
performed EMSA competition experiments (Fig. 5B), using the HNF-4α consensus binding 
site as a radiolabelled probe and increasing molar excesses of unlabelled competitor 
oligonucleotides. The binding of nuclear proteins to the HNF-4α consensus binding site was 
dose-dependently reduced after addition of CNT1 competitor probe containing each wild-type 
DR-1 element. Mutated DR-1 elements were not able to compete for binding of nuclear 
proteins to the HNF-4α consensus binding site. These data indicate that HNF-4α is capable of 
binding to both HNF-4α -responsive DR-1 elements in the proximal CNT1 promoter sequence 
in vitro. 
PGC-1α coactivates CNT1 promoter activity via the HNF-4α response elements. The 
transcriptional cofactor PGC-1α is a known coactivator of HNF-4α in the context of the 
phosphoenolpyruvate carboxykinase (PEPCK) promoter (63). To test whether PGC-1α is also 
involved in the HNF-4α -dependent transcriptional regulation of CNT1 gene expression, we 
cotransfected Huh7 cells with reporter-linked CNT1 promoter constructs, either with or without 
expression plasmids for HNF-4α and PGC-1α  (Fig. 6A). Cotransfection of PGC-1α increased 
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HNF-4α-mediated upregulation of the CNT1 promoter constructs -2450/+110 and -99/+110, 
whereas cotransfection of PGC-1α alone without HNF-4α did not affect the activity of the 
CNT1 promoter. Mutagenesis of the two identified DR-1 elements in the mut-99/+110 CNT1 
promoter construct abolished the activation of promoter activity by HNF-4α and PGC-1α. 
These data show PGC-1α is a coactivator of HNF-4α in the context of the CNT1 promoter.  
SHP represses CNT1 promoter activity via the HNF-4α response elements. The bile 
acid-inducible transcriptional corepressor SHP has been shown to suppress expression levels of 
several HNF-4α-regulated drug transporter genes (10). To study whether this regulatory 
mechanism is also involved in controlling CNT1 gene expression, we cotransfected Huh7 cells 
with reporter-linked CNT1 promoter constructs, either with or without expression plasmids for 
HNF-4α and SHP (Fig. 6B). Cotransfection of SHP reduced the HNF-4α-mediated increase of 
the CNT1 promoter constructs -2450/+110 and -99/+110. Cotransfection of SHP had no effect 
on the CNT1 promoter construct mut-99/+110, in which both DR-1 binding elements were 
mutated. Cotransfection of SHP alone without HNF-4α had no effect on CNT1 promoter 
activity. These results demonstrate that SHP is capable of repressing CNT1 promoter activity, 
in a manner dependent on the two intact DR-1 elements at positions -71/-59 and -55/-43. 
Bile acids suppress CNT1 expression levels. SHP expression levels are known to be 
increased after bile acid treatment via a FXR/RXR-dependent pathway (52) To test whether 
bile acids are capable of regulating endogenous CNT1 gene expression, we treated primary 
human hepatocytes with or without the bile acid chenodeoxycholic acid (CDCA) for 16 hours 
and measured mRNA expression levels using quantitative TaqMan PCR (Fig. 7). The mRNA 
expression levels of CNT1 were significantly reduced after the CDCA treatment. As expected, 
bile acids induced endogenous SHP mRNA expression levels in primary human hepatocytes. 
HNF-4α mRNA expression levels were also negatively affected by bile acids, an effect that has 
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been previously observed in rat livers (62) and the liver-derived human cell line Huh7 (48). 
Furthermore, we measured mRNA expression levels of two known bile acid-regulated 
transporter genes NTCP and OATP1B3 as controls for the treatment. Our results are consistent 
with previously published data suggesting that human NTCP (9) and rat Ntcp (59) expression 
is suppressed upon CDCA treatment via a SHP-dependent mechanism, whereas OATP1B3 
expression is known to be induced after bile acid treatment (26). These data are in agreement 
with our results from the cotransfection experiments, which showed that exogenous SHP 
expression represses CNT1 promoter activity.  
Cnt1 expression levels are altered in ileum and kidneys in two mouse models of 
cholestasis. Our in silico analysis of the proximal CNT1/Cnt1 promoter indicated that the two 
identified bile acid-responsive DR-1 elements are conserved between humans and rodents (Fig. 
2B). Therefore we investigated whether Cnt1 mRNA expression levels are altered in mice fed a 
cholic acid (CA)-enriched diet or in mice that underwent common bile duct ligation (CBDL). 
As Cnt1 mRNA expression levels in mouse liver samples were unexpectedly almost 
undetectable (data not shown), it was not feasible to analyze differences in hepatic mRNA 
expression levels in mice. In the ileum, mice fed a CA-enriched diet showed significantly 
decreased Cnt1 mRNA levels and a strong induction of Shp mRNA expression (Fig. 8A). Hnf-
4α mRNA expression in ileum was not affected by CA feeding. To evaluate the efficacy of CA 
feeding we measured mRNA expression levels of the ileal bile acid transporters Asbt, Ostα, 
and Ostβ. The Asbt gene encodes for the apical sodium-dependent bile salt transporter in ileal 
enterocytes and its expression has been shown to be suppressed upon bile acid treatment in 
mice (5, 15, 58) and human cells (38). As expected, Asbt mRNA expression in ileum was 
suppressed by CA feeding. The Ostα and Ostβ genes encode the two subunits of the bile acid 
efflux system at the basolateral membrane of ileocytes. Both genes have been reported to be 
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coordinately regulated by bile acids in humans (28) and mice (66). However, we could not 
observe significant differences in ileal Ostα and Ostβ mRNA expression between bile acid- or 
control-fed mice, similarly to what has been described by Frankenberg and coauthors (15). 
CBDL causes a decrease in the bile acid load to ileal enterocytes. Consistent with our 
proposed model, Cnt1 mRNA expression was elevated in the ileum in mice that underwent 
CBDL for one week compared to sham-operated (SOP) mice (Fig. 8B). Shp mRNA expression 
was strongly suppressed, whereas Hnf-4α mRNA expression was unaffected in CBDL mice. 
Ileal Asbt mRNA remained unchanged between SOP und CBDL mice, consistent with 
previous observations (2).  Ostα and Ostβ mRNA levels were both significantly decreased in 
the ileum of mice that underwent CBDL.  
 Unlike in ileum, Cnt1 mRNA expression in kidneys was not affected by feeding mice a 
CA-enriched diet for one week (Fig. 9A). Furthermore, there were no significant differences in 
renal Shp and Hnf-4α mRNA expression between mice fed a control or CA-enriched diet, 
whereas Ostα and Ostβ mRNA levels were elevated in kidneys of CA fed mice, consistent with 
a previous study (66). Cnt1 mRNA expression was significantly suppressed in kidneys of mice 
after one week of CBDL (Fig. 9B), which is known to be associated with increased urinary bile 
acid excretion (36). Shp mRNA expression in the kidneys of SOP (mean threshold cycle value: 
33.8) and CBDL (mean threshold cycle value: 35.1) mice was very low. There was no 
significant difference of Shp expression in kidneys of those two groups, possibly due to the 
high variation in the Shp expression levels within the CBDL group. There was a tendency for 
lower Hnf-4α mRNA expression in kidneys of mice that underwent CBDL, but this effect did 
not reach statistical significance. We could not observe significant differences in renal Ostα  
and Ostβ mRNA expression levels between SOP and CBDL mice.  
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DISCUSSION 
 
 In the current study we have shown that the human nucleoside transporter CNT1 gene is 
regulated by HNF-4α and bile acids. The promoter region of the CNT1 gene was cloned and 
investigated in detail, and the exact transcription start site of the CNT1 gene was defined by 5`-
RACE (Fig.1). Two conserved DR-1 elements in the proximal CNT1 promoter region were 
identified that serve as binding sites for the nuclear receptor HNF-4α (Fig. 2 and 5), which 
transactivates luciferase reporter constructs containing the CNT1 promoter region in cell lines 
derived from human liver (Huh7), kidneys (ACHN) and colon (Caco2) (Fig. 3). Site-directed 
mutagenesis of the DR-1 elements located between nucleotides -71/-59 and -55/-43 resulted in 
a complete loss of HNF-4α-mediated induction of CNT1 promoter activity, whereas 
mutagenesis of either DR-1 element alone did not impair function (Fig. 4). An additional DR-1 
element located between nucleotides -1857/-1845, which is not conserved between humans and 
rodents, emerged not to be required for HNF-4α-mediated regulation of the CNT1 gene (Fig. 
3). Exogenous expression of other transcription factors shown to be capable of binding DR-1 
elements such as PPARα, PPARγ and RXRα (1), did not affect CNT1 promoter activity (data 
not shown). Two cofactors of HNF-4α were shown to be involved in the transcriptional 
regulation of the CNT1 promoter: the coactivator PGC-1α (Fig. 6A) and the bile acid-inducible 
corepressor SHP (Fig. 6B). The transcriptional coactivator PGC-1α is a known cofactor for 
many nuclear receptors and controls a variety of metabolic pathways in several tissues (32). 
The action of both cofactors, PGC-1α and SHP, was shown to be dependent on the two intact 
HNF-4α binding elements in the proximal CNT1 promoter (Fig. 6). SHP gene expression has 
been reported to be activated upon increased bile acid concentrations via a FXR-dependent 
pathway (17, 34, 52). Our data show that endogenous CNT1 mRNA levels were suppressed, 
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while SHP mRNA levels were increased, in primary human hepatocytes upon CDCA treatment 
(Fig. 7).   
 This study adds CNT1 to the list of human drug transporter genes that are regulated by 
the nuclear receptor HNF-4α.. HNF-4α is abundantly expressed in adult liver, pancreas, 
kidneys, and intestine, and controls the expression of many genes involved in glucose, fatty 
acid, and cholesterol metabolism (4), (53). For years HNF-4α was considered an orphan 
member of the nuclear receptor family, but endogenous fatty acids were more recently 
identified to interact with its ligand-binding domain, rendering HNF-4α constitutively active 
(7), (60). HNF-4α binds as a homodimer to DR-1- and DR-2-type DNA-binding motifs in the 
promoter regions of target genes (16).  Several members of the SLC gene family have been 
predicted to be such target genes of HNF-4α in human liver and pancreatic islets by a large 
scale approach using chromatin immunoprecipitations combined with promoter microarrays, 
although CNT1 was not amongst the listed HNF-4α-regulated candidate genes (40). A role of 
the nuclear receptor HNF-4α in the regulation of CNT1 expression has been previously 
suggested from studies on antisense HNF-4α-infected Bc2 cells, which undergo spontaneous 
differentiation in culture: inhibition of HNF-4α expression abolished upregulation of CNT1 
mRNA expression during differentiation (13). The detailed mechanism of HNF-4α-mediated 
transactivation of human drug transporter genes has been described so far only for the OCT1 
(SLC22A1) (51) and OAT2 (SLC22A7) (48) genes in the liver, and the OAT1 (SLC22A6) gene 
(41) in the kidney. Whereas HNF-4α mediates human OAT2 (48) and CNT1 promoter 
transactivation via binding to one or two DR-1 elements, respectively, the HNF-4α response 
elements in the human OCT1 promoter are of the DR-2-type (51). The integrity of the two 
adjacent DR-2 elements was shown to be required for maximal transactivation of the OCT1 
promoter by HNF-4α  (51), whereas in the current study the disruption of only one of the two 
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DR-1 elements in the proximal CNT1 promoter did not impair HNF-4α-mediated increase of 
promoter activity. Hnf-4α and Pgc-1α have been reported to mediate induction of basolateral 
hepatic uptake transporters of the Slc gene family upon fasting in rats (8). Having shown that 
CNT1 promoter activity is increased after cotransfection of HNF-4α and PGC-1α in a number 
of cell lines, we propose that these two factors may be responsible for the observed increase in 
Cnt1 expression in rat jejunum upon starvation (55).  
 Our model of bile acid-mediated regulation of CNT1 gene expression was further 
supported by in vivo data from mice that were fed a CA-enriched diet or underwent CBDL for 
one week (Fig. 8 and 9). Feeding with exogenous bile acids is a common model of 
experimental cholestasis, in which bile acid concentrations are increased selectively without 
affecting other bile constituents. CBDL is another widely-used cholestatic mouse model 
mimicking physical obstruction of the biliary tree (54). CA feeding strongly induced Shp 
mRNA expression and suppressed Cnt1 mRNA expression in mouse ileum.  
 Bile acids undergo efficient cycling between the liver and the intestine. CBDL results in 
reduced presentation of bile salts to the apical surface of enterocytes. Similarly to the CA 
feeding model, ileal Cnt1 and Shp gene expression in CBDL mice is inversely regulated: Cnt1 
expression was significantly increased, whereas Shp expression was diminished to almost 
undetectable limits in ileum of mice that underwent CBDL.  
 CNT1 is highly expressed in human kidneys and bile acid secretion in urine is markedly 
increased in both cholestatic animal models and in clinical cholestatic disorders (30, 36, 49). 
Therefore, we also analysed bile acid-dependent regulation of Cnt1 expression in kidneys of 
cholestatic mouse models. In contrast to the ileum, feeding a CA-enriched diet had no effect on 
either Cnt1 or Shp renal mRNA expression levels. The difference in bile acid-responsiveness 
of Cnt1 in ileum and kidneys of mice after feeding a CA-enriched diet might be explained by 
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the fact that enterocytes were exposed to much higher concentrations of CA than renal tubule 
cells. Even if the levels of serum bile acids were significantly elevated upon CA-feeding (data 
not shown), they may have been modified by phase I and II metabolizing enzymes, before 
reaching the kidneys. Bile acids undergo hydroxylation, sulfation, and glucuronidation to 
increase their water solubility, facilitating their detoxification (25). Such modified bile acids 
may have an altered potency to serve as FXR ligands, and hence to regulate Cnt1 gene 
expression via a Shp-dependent pathway.  
 In addition to the CA feeding mouse model we investigated changes in Cnt1 expression 
in kidneys of CBDL versus SOP mice. CBDL mice are characterized by elevated serum bile 
acid concentrations and increased urinary bile acid excretion rates (36). Cnt1 mRNA 
expression was indeed suppressed upon CBDL in kidneys, consistent with our model. Thus 
renal Cnt1 mRNA expression is only suppressed in the CBDL but not the bile acid feeding 
model. We note that discrepancies in transporter expression in different animal models of 
cholestasis have been reported before (31).  
 Bile acids exert their signalling activity mostly as ligands of the nuclear receptor FXR 
(35, 42, 57), which activates its target promoters via direct binding to FXR response elements. 
One FXR-activated target gene encodes the transcriptional corepressor SHP (52), which we 
propose to mediate the suppressive effects of bile acids on CNT1 gene expression. It should be 
noted that bile acids do also elicit FXR-independent signalling pathways, such as the c-Jun N-
terminal kinase JNK pathway (24), which may contribute to CNT1 gene suppression. In this 
context it is interesting that the activity of HNF-4α has been suggested to be modulated by 
phosphorylation events (23, 56, 61). Furthermore, bile acids may reduce CNT1 gene expression 
by modulating HNF-4α expression. We observed reduced HNF-4α mRNA expression in 
primary human hepatocytes treated with CDCA, an effect that was observed previously in rat 
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livers (62) and the liver-derived human cell line Huh7 (48). However, we were not able to 
detect any significant differences in Hnf-4α mRNA expression in ileum and kidneys in the two 
cholestatic mouse models. Reduced nuclear localisation of Hnf-4α has been described in 
mouse liver after CBDL, but not after CA-feeding (65).  
 In summary (Fig. 10), we have shown that HNF-4α transactivates the CNT1 promoter 
and that the coactivator PGC-1α further increases HNF-4α-dependent CNT1 promoter activity. 
Bile acids suppress CNT1 expression in vitro and in vivo, most likely via increasing the 
expression of the transcriptional corepressor SHP in a FXR/RXR-dependent pathway, thus 
counteracting the HNF-4α-mediated induction of the CNT1 promoter. Based on these results, 
the uptake of nucleoside analogue drugs may be decreased in disease conditions associated 
with elevated intracellular concentrations of bile acids. 
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FIGURE LEGENDS  
 
Fig. 1. Determination of the transcriptional start site of the human CNT1 gene by 5`-
RACE using liver RNA.  A. The 5`-RACE product was cloned into the pGEM-T vector and 
sequenced. B. The position of the exons (E) in the CNT1 sequence is shown. The 
oligonucleotide primer (arrow) used in the 5`-RACE experiment is located in exon 3. C. The 
transcription start site +1 of the CNT1 gene identified by 5`-RACE is located 27 bp upstream 
of the predicted exon 1 according to GenBank submission NM_004213 shown in grey.  
 
Fig. 2.  Identification of putative HNF-4α response elements within the human CNT1 
promoter. A. In the top row, the consensus sequence of a HNF-4α response element DR-1 is 
shown. Sequence and location relative to the transcription start site of the DR-1 like elements 
of the CNT1 promoter are shown. Nucleotides different from the consensus sequence are 
underlined. Mutated DR-1 elements used in figures 4, 5, and 6 are shown below. B. The DR-1 
elements (boxes) -71/-59 and -55/-43 are conserved between human and rodent CNT1/Cnt1 
genes. In the top row, the human sequence containing the two proximal DR-1 elements is 
shown. Nucleotides in the rodent DR-1 elements that differ from the human sequence are 
underlined. 
 
Fig. 3. HNF-4α transactivates the human CNT1 promoter. A. Huh7 B. Caco2 and C. 
ACHN cells were cotransfected with reporter-linked CNT1 promoter deletion constructs, as 
well as the promoterless reporter vector pGL3basic. With each construct, either a CMV 
promoter-driven expression plasmid for HNF-4α or an empty pcDNA3.1(-) vector (control) 
was cotransfected. Relative luciferase activities obtained for pcDNA3.1(-)-transfected cells are 
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set to 1, and the fold activities in other test conditions are shown relative to these. n.s. not 
significant, ***p<0.001. 
 
Fig. 4. Two DR-1 elements within the human CNT1 promoter are functional. Huh7 cells 
were cotransfected with reporter-linked CNT1 promoter construct -99/+110, as well as the 
promoterless reporter vector pGL3basic. DR-1 elements in the promoter constructs were 
mutated (boxes with a cross) by site-directed mutagenesis, either together or separately. With 
each construct, either a CMV promoter-driven expression plasmid for HNF-4α or an empty 
pcDNA3.1(-) vector (control) was cotransfected. Relative luciferase activities obtained for 
pcDNA3.1(-)-transfected cells are set to 1, and the fold activities in other test conditions are 
shown relative to these. n.s. not significant., ***p<0.001. 
 
Fig. 5. HNF-4α specifically binds to the DR-1 elements within the CNT1 promoter.  
A. Electrophoretic mobility shift assays were performed using nuclear extracts (NE) from 
Huh7 cells and the CNT1 sequence containing the wild-type (WT) or mutated (mut) DR-1 
elements as radiolabelled probes. Nucleotide exchanges in mutated probes are shown in the 
sequence below. Probes contained each of the DR-1 elements separately or combined. 
Numbers indicate the position of the probes within the CNT1 promoter relative to the 
transcription start site. To identify protein-DNA complexes specifically formed between 
HNF-4α and the radiolabelled probes, samples preincubated with a HNF-4α antibody were 
included as indicated. B. Competition assays were performed using nuclear extracts (NE) 
from Huh7 cells and a radiolabelled probe containing the HNF-4α consensus binding site. 
Competitor probes containing the CNT1 wild-type (WT) or mutated (mut) DR-1 elements 
were added in a 50-fold, 100-fold or 200-fold molar excess as indicated.  
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Fig. 6. PGC-1α coactivates and SHP represses CNT1 promoter activity. Huh7 cells were 
transfected with the CNT1 promoter constructs -2450/+110, -99/+110, and mutated -99/+110, 
and cotransfected with HNF-4α expression plasmid with or without an expression plasmid for 
A. PGC-1α or B. SHP. Relative luciferase activities obtained for pcDNA3.1(-)-transfected cells 
are set to 1, and the fold activities in other test conditions are shown relative to these. n.s. not 
significant. ***p<0.001. 
 
Fig. 7. Bile acids suppress CNT1 expression levels. Primary human hepatocytes of two 
donors were treated with 50 µM CDCA or the vehicle DMSO for 16 hours before isolating 
total cellular RNA. After reverse transcription, cDNAs were analysed by TaqMan PCR for 
CNT1, SHP, HNF-4α, NTCP, and OATP1B3 expression levels. The signal obtained for the 
DMSO-treated cells was set to 1, and values for CDCA-treated cells are shown relative to this. 
***p<0.001. 
 
Fig. 8. Effects of bile acids on Cnt1 expression in the ileum. Total ileal RNAs were isolated 
from mice A. fed a CA-enriched diet or a standard diet, or B. one week after sham operation 
(SOP) or common bile duct ligation (CBDL). After reverse transcription, cDNAs were 
analysed by TaqMan PCR for Cnt1, Shp, Hnf-4α, Asbt, Ostα, and Ostβ expression levels. 
Expression levels were normalized to villin expression. Values are averages from 4-5 animals 
per group. Data of CA-fed animals are shown relative to data from animals fed a standard diet. 
n.s. not significant. * p<0.05, ** p<0.01, ***p<0.001. 
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Fig. 9. Effects of bile acids on Cnt1 expression in kidneys. Total kidney RNAs were isolated 
from mice A. fed a CA-enriched diet or a standard diet, or B. one week after sham operation 
(SOP) or common bile duct ligation (CBDL). After reverse transcription, cDNAs were 
analysed by TaqMan PCR for Cnt1, Shp, Hnf-4α, Ostα, and Ostβ expression levels. Expression 
levels were normalized to Hprt expression. Values are averages from 4 animals per group. Data 
of CA-fed animals are shown relative to data from animals fed a standard diet. n.s. not 
significant. * p<0.05, ** p<0.01. 
 
Fig. 10. Potential pathways that regulate CNT1 gene expression. Bile acids bind to and 
activate FXR, which heterodimerizes with RXR, and induces the expression of SHP. SHP is a 
corepressor for HNF-4α, which binds to the DR-1 elements in the CNT1 promoter. PGC-1α 
coactivates HNF-4α-mediated induction of CNT1 gene expression. Furthermore, bile acids may 
have a direct, SHP-independent, effect on CNT1 gene expression. 
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Table 1. Sequences of oligonucleotides used for cloning, mutagenesis, and as EMSA probes. 
Only the top strands are shown for oligonucleotides used in EMSA assays. Where applicable, 
restriction sites introduced are underlined and corresponding enzymes used are given in 
parentheses. 
Oligonucleotide Sequence (5’-3’) Purpose 
hCNT1 -2450 for GATACGCGTATAATAGACAGGGACATCACCC (MluI) hCNT1(-2450/+110) cloning 
hCNT1 +110 rev  GATCTCGAGTCCTTTTCTCTCACCCTTGTT (XhoI) hCNT1(-2450/+110) cloning 
hCNT1 -341 for ACGCGTTGGCTTCTGGGGTCTGG (MluI) hCNT1(-341/+110) cloning 
hCNT1 -99 for  ACGCGTTAACTTTGGCAGTCAGGAGTG (MluI) hCNT1(-99/+110) cloning 
hCNT1 -29 for ACGCGTTGTAGAGATTAGGGCCCACAA (MluI) hCNT1(-29/+110) cloning 
hCNT1 +3 rev CTCGAGTCTCTACAACAAGGATTTAATGGGCT (XhoI) hCNT1(-99/+3) cloning 
hHNF-4α for GAATTCGGCCATGGTCAGCGTGAACGC (EcoRI) hHNF-4α  cloning 
hHNF-4α rev GGATCCCTAGATAACTTCCTGCTTGGTGATGG (BamHI) hHNF-4α  cloning 
hSHP for GGATCCATATGAGCACCAGCCAACCAGGGG (BamHI) hSHP cloning 
hSHP rev GAATTCTACCTGAGCAAAAGCATGTCCCCAAGAAG (EcoRI) hSHP cloning 
hCNT1 wt  AGCTAGTGGAGACCTTTGGGCTCCAAGCTCAAGGTCCACCCCA EMSA (-76/-38) 
hCNT1 mut AGCTAGTGGATACTTTTTGGTTCCAAACTAAAGATCAACCCCA EMSA (-76/-38) 
hCNT1 wt AGCTAGTGGAGACCTTTGGGCTCCAAG EMSA (-76/-54) 
hCNT1 mut AGCTAGTGGATACTTTTTGGTTCCAAG EMSA (-76/-54) 
hCNT1 wt AGCTCTCCAAGCTCAAGGTCCACCCCA EMSA (-60/-38) 
hCNT1 mut AGCTCTCCAAACTAAAGTTCTACCCCA EMSA (-60/-38) 
HNF-4α consensus GATCAGGTCTCACAGGTCAAAGGTCACCCTGGGA EMSA 
hCNT1 -55/-43 GAGACCTTTGGGCTCCAAACTAAAGTTCTACCCCAAGAC hCNT1(-99/+110)  mutagenesis 
hCNT1 -71/-59 GTCAGGAGTGGATACTTTTTGGTTCCAAGCTCAAGGTCC hCNT1(-99/+110)  mutagenesis 
hCNT1 -71/-43 CAGGAGTGGATACTTTTTGGTTCCAAACTAAAGATCAACCCCAAGAC hCNT1(-99/+110)  mutagenesis 
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hCNT1 exon3 rev GCCCCCATGTTCTCCAGACCCTTGGCC 5`-RACE 
 
  
 
Supplemental Table 1: Mean treshold cycle (Ct) values (± SD) for control samples for of each 
gene used in TaqMan PCR experiments are shown.  
 
 
Figure 7 
gene Donor 1: Ct ± SD   Donor 2: Ct ± SD 
CNT1 29.1 ± 0.05 28.6 ± 0.09 
SHP 31.3 ± 0.09 28.0 ± 0.04 
HNF-4α 26.2 ± 0.01 25.5 ± 0.05 
NTCP 26.4 ± 0.08 24.0 ± 0.03 
OATP1B3 29.2 ± 0.28 30.6 ± 0.24 
Figure 8A 
gene Ct ± SD   
Cnt1 32.4 ± 0.85 
Shp  33.2 ± 1.6 
Hnf-4α 24.6 ± 0.97 
Asbt 23.1 ± 1.03 
Ostα 24.8 ± 0.97 
Ostβ 23.6 ± 1.6 
Figure 8B 
gene Ct ± SD   
Cnt1 32.2 ± 2.04 
Shp  30.7 ± 2.29 
Hnf-4α 23.6 ± 0.45 
Asbt 23.4 ± 0.21 
Ostα 23.9 ± 0.45 
Ostβ 23.2 ± 0.44 
Figure 9A 
gene Ct ± SD   
Cnt1 30.9 ± 0.47 
Shp  34.2 ± 0.54 
Hnf-4α 22.9 ± 0.17 
Ostα 27.1 ± 0.29 
Ostβ 27.0 ± 0.09 
Figure 9B 
gene Ct ± SD   
Cnt1 30.2 ± 0.14 
Shp  33.8 ± 0.30 
Hnf-4α 30.2 ± 0.24 
Ostα 26.6 ± 0.43 
Ostβ 26.9 ± 0.22 
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Supplemental figure 1. Basal CNT1 promoter activity: Huh7, Caco2, and ACHN cells 
were transfected with reporter-linked CNT1 promoter deletion constructs, as well as 
promoterless reporter vector pGL3basic. Luciferase activities obtained for pGL3basic-
transfected cells are set to 1, and the fold activities for CNT1 promoter deletion constructs are 
shown relative to these.  
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